膦甲酸钠治疗人巨细胞病毒感染相关性进展性卒中的临床研究  

Clinical investigation on PFA applied to treat progressive stroke associated with HCMV active infection

作　　者：周曼云[1] 

机构地区：[1]河北省唐山市丰南区医院神经内科,河北唐山063000

出　　处：《中国民康医学》2010年第22期2829-2830,2849,共3页Medical Journal of Chinese People’s Health

摘　　要：目的：探讨膦甲酸钠（PFA）治疗人巨细胞病毒（HCMV）感染相关性进展性卒中的疗效。方法：57例进展性卒中患者，经外周血白细胞HCMV—pp65抗原检测证实呈HCMV活动性感染状态。所有患者随机分为常规治疗组和PFA治疗组两组。治疗14天后复查。结果：PFA治疗组HCMV—pp65抗原转阴率82．8％（24／29），神经症状改善良好，有效率96．6％（28／29）。两组疗效差异显著（P〈0．05—0．01）。结论：膦甲酸钠是治疗HCMV感染相关性进展性卒中的有效药物。Objective： To investigate the effects of phosphonoformic acid in patients with progressive stroke （PS） associated with Human Cytomegalovirus active infection. Methods：Human cytomegalovirus（HCMV） active infection in 57 patients with progressive stroke were confirmed by detecting HCMV - pp65 antigen in perepberal blood leukocytes. All patients were randomly divided into conventional treat -ment group and PFA treatment group. Results：Rechecking HCMV- pp65 after 14 day＇s treatment,82.8% （24/29）of patients treated by PFA were negative and the nervous symptom improved well ,the difference was significant between two groups which treated by PFA and conventional treatment group. Condusion：PFA is a effective medicine to treat the patients with progressive stroke associated with Human cytomegalovirus active infection.

关 键 词：膦甲酸钠 人巨细胞病毒 进展性卒中 

分 类 号：R743.3[医药卫生—神经病学与精神病学]